Inhibiting angiogenesis is a therapeutic strategy for solid tumors, and strategies including monoclonal antibodies targeting VEGF or VEGFR and small-molecule tyrosine kinase inhibitors that inhibit multiple angiogenic and proliferative pathways are approved for clinical use in a variety of cancer contexts 21, 22. This evidence concerns the gene KDR and cancer.